ERBB3 blockade sensitizes HCC to regorafenib after first-line TKI resistance by inhibiting HIF1A-ABCB1 signaling.

待确认 20 由 12123 发布于 2026/1/27 13:45:55

DOI:10.3350/cmh.2025.0972
作者：Baorui Tao,?Chenhe Yi,?Bo Zhang,?Yan Geng,?Yinchen Gu,?Rongquan Sun,?Xiangyu Wang,?Jing Lin,?Jinhong Chen
文献类型：期刊论文
补充材料：只需要正文

其它数据库

Abstract：Background/aims: Regorafenib is recommended by guidelines and trials as a sequential second-line therapy following progression on first-line sorafenib or lenvatinib in hepatocellular carcino

应助信息

等待求助人确认

求助人未确认前，本求助不能再次应助。36小时后系统将自动确认应助成功。本求助将自动关闭。

8小时前

坐看云起时

a3560983fb4411f0932634735aa3bc31.pdf

9小时前

Book学术机器人

2026/1/27 13:45:55 未找到该文献，机器人已退出，请等待人工下载

2026/1/27 13:45:55 Book学术AI机器人收到请求，开始寻找文献

2026/1/27 13:45:55 已向机器人发送请求

9小时前

12123 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:其它数据库Clinical Approach to Heart Failure with Preserved Ejection Fraction (HFpEF) in South Asia: An Expert Consensus Statement